Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release
Study Type: Treatment
Phase: N/A
NCTID: NCT04771078
Principal Investigator:
Alma Habib
Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM
Study Type: Treatment
Phase: II/III
NCTID: NCT05549297
Principal Investigator:
Gary Doolittle
NECTINIUM-2: A Phase Ib, 2-part, Multicenter, Single-arm, Open label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical 225Ac Ac-AKY-1189 in Patients with Previously Treated Locally Advanced or Metastatic Solid Tumors
Study Type: Treatment
Phase: I/II
NCTID: NCT07020117
Principal Investigator:
Haoran Li
An Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T cells Recognizing KRAS Mutations in Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors
Study Type: Treatment
Phase: I
NCTID: NCT06218914
Principal Investigator:
Joaquina Baranda
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab REGN2810 for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Lung-MAP Non-Matched Sub-Study
Study Type: Treatment
Phase: II/III
NCTID: NCT06616584
Principal Investigator:
Anusha Chidharla
A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells MT-601 Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma NHL [APOLLO]
Study Type: Treatment
Phase: I
NCTID: NCT05798897
Principal Investigator:
Haitham Abdelhakim
A Randomized Phase III Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin with or without Venetoclax in Children with Relapsed AML
Study Type: Treatment
Phase: III
NCTID: NCT05183035
Principal Investigator:
Kevin Ginn
A Phase III, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Na�ve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Study Type: Treatment
Phase: III
NCTID: NCT06479135
Principal Investigator:
Abdulraheem Yacoub
FORTE Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Study Type: Prevention
Phase: III
NCTID: NCT05080673
Principal Investigator:
Ajay Bansal
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations Excluding Melanoma and Thyroid Cancer
Study Type: Treatment
Phase: II
NCTID: NCT02465060
Principal Investigator:
Benjamin Powers